The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: A community perspective of patients with clinically diagnosed TTP-HUS
George JN, Vesely SK, Terrel DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004;41:60-7.
Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation, and cancer
George JN, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B. Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation, and cancer. Presse Med 2012;41:e177-88.
Ticlopidine and clopidogrel associated thrombotic thrombocytopenic purpura (TTP): Review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008)
Zakarija A, Kwaan HC, Moake JL, et al. Ticlopidine and clopidogrel associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 2009;75:S20-4.
Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis induced disseminated intravascular coagulation: Its correlation with development of renal failure
Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006;107:528-34.
Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenia purpura
Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M, Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenia purpura. J Hepatology 2005;42:420-1.
Drug Enforcement Administration, Washington, DC: US Department of Justice, Drug Enforcement Administration; 2011. Available at
Drug Enforcement Administration. Oxymorphone. Washington, DC: US Department of Justice, Drug Enforcement Administration; 2011. Available at http://www.deadiversion.usdoj.gov/drugs_concern/oxymorphone.pdf.